CAR-NK-92 cell-based therapy is currently being evaluated in clinical trials for CD33+ acute myeloid leukemia (AML; NCT02944162) and CD7+ leukemia and lymphoma (NCT02742727). Here, CD7 is linked to acute myeloid leukemia.